Portal de Periódicos da CAPES

Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort

2015; European Respiratory Society; Volume: 46; Issue: 5 Linguagem: Inglês

10.1183/13993003.00779-2015

1399-3003

Dominick Shaw, Ana R. Sousa, Stephen J. Fowler, Louise Fleming, Graham Roberts, Julie Corfield, Ioannis Pandis, Aruna T. Bansal, Elisabeth H. Bel, Charles Auffray, Chris Compton, Hans Bisgaard, Enrica Bucchioni, Massimo Caruso, Pascal Chanez, Barbro Dahlén, Barbro Dahlén, Kerry Dyson, Urs Frey, Thomas Geiser, Maria Gerhardsson de Verdier, David Gibeon, Yi-ke Guo, Simone Hashimoto, Gunilla Hedlin, E. Jeyasingham, Pieter‐Paul Hekking, Tim Higenbottam, Ildikó Horváth, Alan J. Knox, Norbert Krug, Veit J. Erpenbeck, Lars X. Larsson, Nikolaos Lazarinis, John G. Matthews, Roelinde Middelveld, Paolo Montuschi, Jacek Musiał, David Myles, Laurie Pahus, Thomas Sandström, Wolfgang Seibold, Florian Singer, Karin Strandberg, Jørgen Vestbo, Nadja Hawwa Vissing, Christophe von Garnier, Ian M. Adcock, Scott Wagers, Anthony Rowe, Peter Howarth, Ariane H. Wagener, Ratko Djukanović, Peter Sterk, Kian Fan Chung,

Delphi Technique in Research

U-BIOPRED is a European Union consortium of 20 academic institutions, 11 pharmaceutical companies and six patient organisations with the objective of improving the understanding of asthma disease mechanisms using a systems biology approach. This cross-sectional assessment of adults with severe asthma, mild/moderate asthma and healthy controls from 11 European countries consisted of analyses of patient-reported outcomes, lung function, blood and airway inflammatory measurements. Patients with severe asthma (nonsmokers, n=311; smokers/ex-smokers, n=110) had more symptoms and exacerbations compared to patients with mild/moderate disease (n=88) (2.5 exacerbations versus 0.4 in the preceding 12 months; p<0.001), with worse quality of life, and higher levels of anxiety and depression. They also had a higher incidence of nasal polyps and gastro-oesophageal reflux with lower lung function. Sputum eosinophil count was higher in severe asthma compared to mild/moderate asthma (median count 2.99% versus 1.05%; p=0.004) despite treatment with higher doses of inhaled and/or oral corticosteroids. Consistent with other severe asthma cohorts, U-BIOPRED is characterised by poor symptom control, increased comorbidity and airway inflammation, despite high levels of treatment. It is well suited to identify asthma phenotypes using the array of “omic” datasets that are at the core of this systems medicine approach.